STOCK TITAN

NeuroMetrix, Inc. - NURO STOCK NEWS

Welcome to our dedicated page for NeuroMetrix news (Ticker: NURO), a resource for investors and traders seeking the latest updates and insights on NeuroMetrix stock.

NeuroMetrix, Inc., based in Waltham, Massachusetts, is a leading innovator in the healthcare sector, focusing on the development and commercialization of neurotechnology devices. Founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and Technology, the company uniquely combines bioelectrical and digital medicine to address chronic health conditions such as chronic pain, sleep disorders, and diabetes.

The company's flagship product, Quell®, is a wearable neuromodulation platform that offers drug-free pain relief through clinical-grade neurostimulation. Quell® is designed to help individuals suffering from chronic back pain, arthritic pain, nerve pain, and other chronic pain conditions manage their symptoms effectively. Its user-friendly app further aids patients in reclaiming their quality of life.

Another notable product is DPNCheck®, a point-of-care screening test designed for peripheral neuropathy, particularly in diabetic patients. This device has become an essential tool for early diagnosis and management of neuropathy.

NeuroMetrix continues to invest in research and development, maintaining several pipeline programs aimed at expanding their product offerings and improving existing technologies. The company’s current projects include refining their wearable devices to integrate more advanced features, enhancing user experience through mobile apps, and leveraging cloud-based systems for data analysis and management.

Additionally, NeuroMetrix has established significant partnerships and collaborations to expand its market reach and enhance its technological capabilities. Despite the challenges highlighted in recent news, including shareholder concerns about stock valuation and leadership, the company remains focused on delivering innovative healthcare solutions.

For more updates and detailed information on NeuroMetrix's performance, events, and developments, visit NeuroMetrix.com.

Rhea-AI Summary
NeuroMetrix, Inc. plans to release its Q3 2023 business and financial highlights on October 26, 2023. The company will host a conference call at 8:00 a.m. Eastern Time on the same day. Participants can register in advance to join the call and access the webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
NeuroMetrix, Inc. announces sponsorship of the National Fibromyalgia Association, supporting their mission to provide education and support for fibromyalgia patients. Partnership will promote Quell Fibromyalgia and other treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
none
-
Rhea-AI Summary
NeuroMetrix to present at Emerging Growth Conference on October 4, 2023, providing business update and Quell® technology evolution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.2%
Tags
conferences acquisition
Rhea-AI Summary
NeuroMetrix to present at Emerging Growth Conference on September 6, 2023, highlighting business developments and Quell® technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
conferences acquisition
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags

FAQ

What is the current stock price of NeuroMetrix (NURO)?

The current stock price of NeuroMetrix (NURO) is $3.95 as of December 23, 2024.

What is the market cap of NeuroMetrix (NURO)?

The market cap of NeuroMetrix (NURO) is approximately 8.0M.

What does NeuroMetrix, Inc. specialize in?

NeuroMetrix specializes in developing neurotechnology devices to address chronic pain, sleep disorders, and diabetes.

What are the main products offered by NeuroMetrix?

The main products are Quell®, a wearable neuromodulation platform, and DPNCheck®, a point-of-care screening test for peripheral neuropathy.

Where is NeuroMetrix located?

NeuroMetrix is located in Waltham, Massachusetts.

When was NeuroMetrix founded?

NeuroMetrix was founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and Technology.

What is Quell® used for?

Quell® is used for drug-free pain relief through clinical-grade neurostimulation, effective for chronic back pain, arthritic pain, nerve pain, and other chronic pain conditions.

What is DPNCheck®?

DPNCheck® is a point-of-care screening test for peripheral neuropathy, which is particularly essential for diabetic patients.

Does NeuroMetrix have any ongoing research projects?

Yes, NeuroMetrix maintains active research efforts and has several pipeline programs aimed at expanding their product offerings and improving existing technologies.

How can I get more information about NeuroMetrix?

For more detailed information, you can visit the company's official website at www.NeuroMetrix.com.

What recent achievements has NeuroMetrix announced?

Recently, NeuroMetrix announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022.

What challenges is NeuroMetrix currently facing?

NeuroMetrix is currently addressing shareholder concerns about stock valuation, leadership decisions, and overall strategic direction.

NeuroMetrix, Inc.

Nasdaq:NURO

NURO Rankings

NURO Stock Data

7.97M
1.59M
25.45%
3.01%
2.08%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
WALTHAM